The Role of SBDP Protein as a Potential Biomarker for Early-Onset Subarachnoid Hemorrhagic.

IF 2.4 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Ita M Sari, Selfy Oswari, Paulus A Ong, Achmad Adam, Nur Atik
{"title":"The Role of SBDP Protein as a Potential Biomarker for Early-Onset Subarachnoid Hemorrhagic.","authors":"Ita M Sari, Selfy Oswari, Paulus A Ong, Achmad Adam, Nur Atik","doi":"10.3390/medicina61030454","DOIUrl":null,"url":null,"abstract":"<p><p><i>Background and Objectives:</i> Cerebral vasospasm is the most common complication of subarachnoid hemorrhage (SAH) that is related to high mortality and morbidity. Early biomarkers predicting those conditions are still limited. This study aims to analyze spectrin degradation products (SBDPs) as potential biomarkers for SAH patients, which can be used to monitor clinical outcomes. <i>Materials and Methods:</i> We conducted a prospective observational study in acute SAH within 72 h of onset. All patients underwent placement of continuous cerebrospinal drainage, and liquor was taken four times and analyzed using ELISA to measure SBDP150, SBDP145, and SBDP120 levels and analyzed using Friedman test and post hoc Wilcoxon analysis. The relationship between SBDP levels and vasospasm, as well as functional outcomes (using the Glasgow Outcome Scale-Extended, GOSE), was assessed. <i>Results:</i> We enrolled thirty-five patients: thirty patients with lumbar drainage (LD) and five with extra ventricular drainage (EVD). Friedman's analysis showed significant changes over time for SBDP120 (<i>p</i> = 0.0001) and SBDP145 (<i>p</i> = 0.0001), but not for SBDP150 (<i>p</i> = 0.218). Levels of SBDP120 on day 3 (<i>p</i> = 0.001), SBDP120 on day 5 (<i>p</i> = 0.022), and SBDP145 on day 3 (<i>p</i> = 0.005) in EVD group were higher than in the LD group. SBDP145 on day 5 was significantly higher in patients with vasospasm (<i>p</i> = 0.041 in all patients, <i>p</i> = 0.028 in LD patients), indicating its potential as an early biomarker for vasospasm. SBDP145 on day 7 (<i>p</i> = 0.014) is the strongest predictor of unfavorable GOSE at 90 days in all patients. In LD patients, SBDP145 on day 7 (<i>p</i> = 0.002), SBDP120 on day 7 (<i>p</i> = 0.009), and SBDP120 on day 10 (<i>p</i> = 0.043) were significantly associated with poor GOSE at 90 days. <i>Conclusions:</i> A higher level of SBDP145 on day 5 can predict vasospasm risk, while an elevated level of SBDP145 and SBDP120 on day 7 is a potential predictor of poor functional outcomes. SBDPs may serve as valuable biomarkers for SAH management.</p>","PeriodicalId":49830,"journal":{"name":"Medicina-Lithuania","volume":"61 3","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11944217/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina-Lithuania","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/medicina61030454","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Objectives: Cerebral vasospasm is the most common complication of subarachnoid hemorrhage (SAH) that is related to high mortality and morbidity. Early biomarkers predicting those conditions are still limited. This study aims to analyze spectrin degradation products (SBDPs) as potential biomarkers for SAH patients, which can be used to monitor clinical outcomes. Materials and Methods: We conducted a prospective observational study in acute SAH within 72 h of onset. All patients underwent placement of continuous cerebrospinal drainage, and liquor was taken four times and analyzed using ELISA to measure SBDP150, SBDP145, and SBDP120 levels and analyzed using Friedman test and post hoc Wilcoxon analysis. The relationship between SBDP levels and vasospasm, as well as functional outcomes (using the Glasgow Outcome Scale-Extended, GOSE), was assessed. Results: We enrolled thirty-five patients: thirty patients with lumbar drainage (LD) and five with extra ventricular drainage (EVD). Friedman's analysis showed significant changes over time for SBDP120 (p = 0.0001) and SBDP145 (p = 0.0001), but not for SBDP150 (p = 0.218). Levels of SBDP120 on day 3 (p = 0.001), SBDP120 on day 5 (p = 0.022), and SBDP145 on day 3 (p = 0.005) in EVD group were higher than in the LD group. SBDP145 on day 5 was significantly higher in patients with vasospasm (p = 0.041 in all patients, p = 0.028 in LD patients), indicating its potential as an early biomarker for vasospasm. SBDP145 on day 7 (p = 0.014) is the strongest predictor of unfavorable GOSE at 90 days in all patients. In LD patients, SBDP145 on day 7 (p = 0.002), SBDP120 on day 7 (p = 0.009), and SBDP120 on day 10 (p = 0.043) were significantly associated with poor GOSE at 90 days. Conclusions: A higher level of SBDP145 on day 5 can predict vasospasm risk, while an elevated level of SBDP145 and SBDP120 on day 7 is a potential predictor of poor functional outcomes. SBDPs may serve as valuable biomarkers for SAH management.

SBDP蛋白作为早发型蛛网膜下腔出血的潜在生物标志物的作用。
背景和目的:脑血管痉挛是蛛网膜下腔出血(SAH)最常见的并发症,具有高死亡率和高发病率。预测这些疾病的早期生物标志物仍然有限。本研究旨在分析光谱降解产物(sbdp)作为SAH患者潜在的生物标志物,可用于监测临床结果。材料和方法:我们在急性SAH发病72小时内进行了一项前瞻性观察研究。所有患者均行持续脑脊液引流术,取液4次,ELISA检测SBDP150、SBDP145、SBDP120水平,采用Friedman检验和事后Wilcoxon分析。评估SBDP水平与血管痉挛以及功能结局(使用格拉斯哥结局扩展量表,GOSE)之间的关系。结果:我们纳入了35例患者:30例腰椎引流(LD), 5例心室外引流(EVD)。Friedman的分析显示,随着时间的推移,SBDP120 (p = 0.0001)和SBDP145 (p = 0.0001)发生了显著变化,但SBDP150没有变化(p = 0.218)。EVD组第3天SBDP120 (p = 0.001)、第5天SBDP120 (p = 0.022)、第3天SBDP145 (p = 0.005)水平均高于LD组。血管痉挛患者第5天的SBDP145显著升高(所有患者的p = 0.041, LD患者的p = 0.028),表明其可能作为血管痉挛的早期生物标志物。在所有患者中,第7天的SBDP145 (p = 0.014)是90天不良GOSE的最强预测因子。在LD患者中,第7天的SBDP145 (p = 0.002)、第7天的SBDP120 (p = 0.009)和第10天的SBDP120 (p = 0.043)与第90天的不良GOSE显著相关。结论:第5天较高的SBDP145水平可以预测血管痉挛风险,而第7天较高的SBDP145和SBDP120水平是功能不良结局的潜在预测因子。sdbps可能作为SAH管理的有价值的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medicina-Lithuania
Medicina-Lithuania 医学-医学:内科
CiteScore
3.30
自引率
3.80%
发文量
1578
审稿时长
25.04 days
期刊介绍: The journal’s main focus is on reviews as well as clinical and experimental investigations. The journal aims to advance knowledge related to problems in medicine in developing countries as well as developed economies, to disseminate research on global health, and to promote and foster prevention and treatment of diseases worldwide. MEDICINA publications cater to clinicians, diagnosticians and researchers, and serve as a forum to discuss the current status of health-related matters and their impact on a global and local scale.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信